Ars Pharmaceuticals targets cash flow breakeven by year-end 2027 as neffy U.S. share surpasses 5%

ARS Pharmaceuticals Q3 2026: neffy sales and market share rose as costs fell, supporting 2027 breakeven goals.

CryptoAlerta — análise de criptomoedas e mercado em tempo real